M&A Deal Summary

Keensight Capital Acquires Axxam

On July 28, 2022, private equity firm Keensight Capital acquired life science company Axxam from Bayer and Zambon Company

Acquisition Highlights
  • This is Keensight Capital’s 6th transaction in the Life Science sector.
  • This is Keensight Capital’s 2nd transaction in Italy.

M&A Deal Summary
Date 2022-07-28
Target Axxam
Sector Life Science
Buyer(s) Keensight Capital
Sellers(s) Bayer
Zambon Company
Deal Type Divestiture

Target

Axxam

Bresso, Italy
Axxam is an iPRO (innovative Partner Research Organization) and discovery company located in the scientific campus OpenZone. The Company is a provider of discovery services for the entire life sciences industry. Axxam has strong expertise across a broad range of discovery disciplines and innovative technologies, including assay development, compound management, HTS (high-throughput screening) / HCS (high content screening), hit identification and hit validation. Axxam is also engaged in developing novel innovative therapies for diseases with a high unmet medical need. Axxam was founded in 2001 and is based in Bresso, Italy.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Keensight Capital

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2000
PE ASSETS 5.5B EUR
Size Mega
Type Sector Agnostic
DESCRIPTION

Keensight Capital is a private equity investment firm focused on majority and minority growth capital investments in Western European companies. Keensight makes equity investments in a number of situations including the provision of capital to finance growth, either organically or through acquisitions, or the buying out of existing shareholders. The Firm looks to invest €10 to €600 million and will consider business with up to €400 million in revenue. Keensight Capital was formed in 2000 and is based in Paris.

DEAL STATS #
Overall 39 of 50
Sector (Life Science) 6 of 9
Type (Divestiture) 3 of 4
Country (Italy) 2 of 2
Year (2022) 6 of 8
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-07-22 BYG4lab

L'Union, France

BYG4lab is a software publisher specializing in medical biology middleware solutions. The Company provides a number of key benefits, including but not limited to: improving workflow management, making instrument integration more efficient, handling mega lab configuration, designing personalized dashboards, maximizing automatic validation, and managing quality control. The Company addresses both Central Lab and Point of Care testing, as well as all disciplines in the field of medical biology – immunochemistry, hematology, molecular, microbiology. BYG4lab was founded in 1982 and is based in L'Union, France.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-10-26 Unither Pharmaceuticals

Amiens, France

Unither Pharmaceuticals is a developer and manufacturer of pharmaceuticals products. Unither operates six manufacturing sites in France, the United States, and Brazil, and has a dedicated research and development center in Europe. Unither Pharmaceuticals was founded in 1993 and is based in Amiens, France.

Sell -

Seller(S) 2

SELLER

Bayer

Leverkusen, Germany
Category Company
Founded 1863
Sector Life Science
Employees98,189
Revenue 47.6B EUR (2023)
DESCRIPTION
Bayer office building in North Sydney, Australia.
Bayer office building in North Sydney, Australia.

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer was founded in 1863 and is based in Leverkusen, Germany.

DEAL STATS #
Overall 21 of 23
Sector (Life Science) 6 of 6
Type (Divestiture) 17 of 19
Country (Italy) 1 of 1
Year (2022) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-07-14 Nebido

Leverkusen, Germany

Nebido provides treatment of male hypogonadism (testosterone deficiency) is based in Leverkusen, Germany.

Sell €500M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-01-18 Blackford Analysis

Edinburgh, United Kingdom

Blackford Analysis provides infrastructure and access to a rich clinical application (ClinApp) ecosystem focused on imaging and analytics. Blackford Analysis is based in Edinburgh, United Kingdom.

Buy -
SELLER

Zambon Company

Bresso, Italy
Category Company
Founded 1906
Sector Life Science
DESCRIPTION

Zambon Company S.p.A. is a multicultural group with close links to its local markets and the international research community. Zambon a pharmaceutical and chemical multinational with a reputation for inventive and innovative thinking, flexibility and customer focus.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Divestiture) 2 of 2
Country (Italy) 1 of 1
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-07-25 Breath Therapeutics

Munich, Germany

Breath Therapeutics is a clinical stage biopharmaceutical company specializing in advanced inhaled therapeutics for severe respiratory diseases with a high unmet medical need.

Buy €140M
Mergr

Product

Company

Legal